AUTHOR=Zhou Hong , Ma Yipeng , Liu Fenglan , Li Bin , Qiao Dongjuan , Ren Peigen , Wang Mingjun TITLE=Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment JOURNAL=Frontiers in Immunology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1255799 DOI=10.3389/fimmu.2023.1255799 ISSN=1664-3224 ABSTRACT=
New York-esophageal cancer 1 (NY-ESO-1) belongs to the cancer testis antigen (CTA) family, and has been identified as one of the most immunogenic tumor-associated antigens (TAAs) among the family members. Given its ability to trigger spontaneous humoral and cellular immune response and restricted expression, NY-ESO-1 has emerged as one of the most promising targets for cancer immunotherapy. Cancer vaccines, an important element of cancer immunotherapy, function by presenting an exogenous source of TAA proteins, peptides, and antigenic epitopes to CD4+ T cells